Therapy News and Research

RSS

$Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015$

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. hematologist-oncologists and managed care organization (MCO) pharmacy directors agree that survival effect is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in patients with chronic myeloid leukemia who have failed first-line tyrosine kinase inhibitor therapy.

19 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Merz launches new, once daily Mederma Advanced Scar Gel

Mederma, the #1 doctor-and pharmacist-recommended brand for scars for over a decade, announced today the introduction of Mederma Advanced Scar Gel, which reduces the overall appearance of scars caused by injury, acne, surgery or burns with just one daily application. Mederma Advanced Scar Gel contains Cepalin, the same proprietary botanical extract derived from onions used in all Mederma® scar products and stretch marks therapy.

19 Mar 2012

BSD-500 Hyperthermia System installed at Fort Belvoir Community Hospital

BSD Medical Corporation announced today the purchase, installation and acceptance of a BSD-500 Hyperthermia System (BSD-500) by Fort Belvoir Community Hospital (Fort Belvoir).

19 Mar 2012

IOB, Delcath to launch CHEMOSAT system for Spanish cancer patients

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain.

19 Mar 2012

Prostate Center of Academic Urology receives accreditation from ACR, ASTRO

The Prostate Center of Academic Urology has been awarded a three-year term of accreditation in radiation oncology from the American College of Radiology (ACR) and The American Society for Radiation Oncology.

19 Mar 2012

Exercise can induce sexual pleasure, female orgasm

Findings from a first-of-its-kind study by Indiana University researchers confirm anecdotal evidence that exercise -- absent sex or fantasies -- can lead to female orgasm.

19 Mar 2012

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

19 Mar 2012

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

Study reveals how Bdnf gene mutation contributes to severe obesity

Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite.

19 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012

Clinicians to discuss best approaches for future cancer treatment at Brainlab's radiotherapy meeting

Today clinicians from around the world will gather at the 4th Brainlab European Radiotherapy User Meeting to share their best practice and experiences in treating difficult-to-treat cancers using advanced radiotherapy.

17 Mar 2012

BC BS of Florida retires negative medical policy for FeNO testing

Aerocrine AB announces that BlueCross BlueShield (BC BS) of Florida1 has retired/archived their negative medical policy for FeNO testing. The change is effective March 15, 2012.

17 Mar 2012

SBMT announces 2012 recipients of Pioneers in Medicine, Technology and Healthcare Policy Awards

Today, the Society for Brain Mapping & Therapeutics announced the 2012 recipients of the organization's prestigious Pioneers in Medicine, Technology, and Healthcare Policy Awards.

17 Mar 2012

Study identifies primary care skills and competencies in opioid risk management

Primary care physicians are faced with treating a large proportion of chronic pain patients, but many do not often have specific training in the assessment and management of chronic pain, including the use of opioid medications for chronic pain management.

17 Mar 2012

WASM, Philips partner to raise awareness of sleep disorders

Royal Philips Electronics will join with the World Association of Sleep Medicine (WASM) as an official sponsor of World Sleep Day 2012, held on Friday, March 16. This year's theme– 'Breathe Easily, Sleep Well' – centers on raising awareness of sleep disorders that affect a person's breathing, such as obstructive sleep apnea.

17 Mar 2012

PFO closure device no better than drugs alone in preventing recurrent strokes or TIAs

Loyola University Medical Center is one of the major enrollers in a landmark clinical trial that found that plugging a hole in the heart works no better than drugs in preventing strokes.

17 Mar 2012

$Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy$

Enrollment commences in MORE Registry for DBS in patients with refractory epilepsy

Medtronic, Inc. today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy.

From Medtronic 17 Mar 2012

Deletion of Hms1 protein inhibits Candida albicans infection

Scientists at the University of Toronto have found a molecular mechanism that plays a key role in the transition of Candida albicans yeast into disease-causing fungus-one of the leading causes of hospital-acquired infection.

17 Mar 2012